Interferon gamma-1b
Also known as: Actimmune, IFN-γ1b, IFNG, Interferon gamma-1b, rhu IFN-gamma, rIFN-γ1b
Source Interferon gamma-1b at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Interferon gamma‑1b (IFN‑γ1b) is a recombinant cytokine prescribed for chronic granulomatous disease (CGD) and investigated for other rare disorders. It is administered by injection to boost immune cell function, reduce serious infections in CGD, and has been studied as a potential antifibrotic agent in idiopathic pulmonary fibrosis and as a bridge therapy before hematopoietic stem‑cell transplantation in infantile osteopetrosis.
Mechanism of Action
IFN‑γ1b binds the interferon‑γ receptor (IFNGR) on immune cells, activating the JAK1/2‑STAT1 signaling cascade. This up‑regulates expression of genes involved in macrophage activation, enhances NADPH‑oxidase activity in phagocytes, and shifts the Th1/Th2 balance toward a Th1 phenotype. In fibrotic tissues, IFN‑γ can inhibit fibroblast proliferation and collagen synthesis, contributing to its proposed antifibrotic effects.
What the Research Shows
A placebo‑controlled trial in CGD patients showed that long‑term IFN‑γ1b reduced the incidence of serious infections, hospital days, and duration of stays, with the greatest benefit in children under ten years; adverse events were mild and transient. In idiopathic pulmonary fibrosis, preclinical data supported an antifibrotic role, but clinical trials yielded mixed results—some improvement in survival in the largest study but inconsistent changes in lung function, and occasional respiratory failure episodes. GeneReviews notes IFN‑γ1b may be used as a temporary bridge to hematopoietic stem‑cell transplantation in infantile TCIRG1‑related osteopetrosis. A single study of IFN‑γ1b in Friedreich ataxia was identified in a systematic review, but outcomes were inconclusive.
Reported Benefits
In CGD, IFN‑γ1b has demonstrated a significant reduction in serious infection rates and hospital utilisation, offering a disease‑modifying benefit. Early‑stage idiopathic pulmonary fibrosis may experience modest survival advantage, although functional improvements are uncertain. In infantile osteopetrosis, the drug can serve as a temporising measure before definitive stem‑cell transplantation, potentially stabilising disease while awaiting curative therapy.
Limitations of the Evidence
Evidence for IFN‑γ1b in pulmonary fibrosis is inconsistent, with variable effects on lung function and isolated reports of respiratory failure. Data in osteopetrosis are limited to expert recommendations rather than controlled trials, and its role remains adjunctive. The Friedreich ataxia study was solitary and did not demonstrate clear efficacy. Overall, the therapeutic scope beyond CGD remains investigational with few high‑quality trials.
Safety Considerations
Common adverse effects include fever, chills, headache, and injection‑site erythema, typically mild and self‑limited. In pulmonary fibrosis studies, transient respiratory failure has been reported following administration. Overall tolerability is acceptable, but clinicians should monitor for systemic flu‑like symptoms and manage them symptomatically. No new safety signals were identified in the CGD trial.
How It Is Administered
IFN‑γ1b is supplied as a sterile recombinant protein for subcutaneous or intramuscular injection. Dosing regimens vary by indication and are determined by the prescribing clinician. The formulation requires refrigeration and reconstitution prior to administration.
Routes of Administration
Goals & Uses
- Reduction of serious infections in chronic granulomatous diseaseImmunodeficiency / Infection ProphylaxisHigh
- Antiviral / antitumor immunotherapyOncology / AntiviralLow
- Adjunct in refractory infectionsInfectious DiseaseModerate
- Chronic Granulomatous DiseaseImmunodeficiencyHigh
- Severe Malignant OsteopetrosisBone DisorderHigh
- Treatment of idiopathic pulmonary fibrosisFibrosis / Pulmonary DiseaseLow
- Delay of disease progression in severe malignant osteopetrosisBone Disease / ImmunomodulationModerate
Contraindications
- Pre-existing severe neurological or seizure disordersNeurologicalModerate
- Hypersensitivity to interferon gamma-1bAllergyHigh
- Severe hepatic impairmentOrganModerateLiver function concerns
- Severe autoimmune diseaseImmunologicalModerate
- Pre-existing severe cardiac diseaseCardiovascularModerate
- Hypersensitivity to interferon-gamma or E. coli-derived proteinsAllergy / ImmunologyHigh
Adverse Effects
- Elevated liver enzymes (AST/ALT)HepatotoxicityUncommon
- Injection site reactionsLocalCommon
- Central nervous system effects (decreased mental status, gait disturbance, dizziness)NeurologicalUncommon
- Neutropenia / thrombocytopeniaHematologicUncommon
- NeutropeniaHematologicRareLow neutrophil count
- Flu-like symptoms (fever, chills, myalgia, headache, fatigue)Systemic / ConstitutionalCommon
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- Flu‑like syndrome (fever, chills, myalgia)SystemicCommon
- Cardiovascular effects (hypotension, tachycardia, syncope)CardiovascularRare
Drug Interactions
- Immunosuppressants (e.g., azathioprine)Low
- Live vaccinesModerate
- Zidovudine (AZT)Moderate
- CYP450-metabolized drugs (e.g., theophylline, warfarin, phenytoin)Moderate
- Immunosuppressants (e.g., corticosteroids, cyclosporine)Moderate
- Myelosuppressive agents (e.g., azathioprine, cyclophosphamide)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- LactationReproductiveRelative
- Patients with pre-existing autoimmune diseaseAutoimmuneRelative
- Pediatric (≤2 years)AgeRelative
- Pediatric patients < 0.5 m² BSAPediatricRelative
- Elderly patientsAgeRelative
Regulatory Status
- European UnionInvestigationalNot marketed; available via compassionate use programs
- United StatesApprovedApproved: Chronic Granulomatous Disease, Severe Malignant OsteopetrosisMarketed as Actimmune
- United KingdomUnapprovedNo licensed product; can be accessed under special access scheme
FDA approved in 1995 (US); EMA approval withdrawn in 2013, currently available in limited EU markets under compassionate use.
Evidence & Sources
- Journal ArticleModeratePacanowski MA, Amsden GW2005-01-01T00:00:00.000000Z
- Journal ArticleModerateGünther A, et al.2006-01-01T00:00:00.000000Z
- Journal ArticleModerateAdam MP, et al.1993-01-01T00:00:00.000000Z
- Journal ArticleModerateTodd PA, Goa KL1992-01-01T00:00:00.000000Z
- Journal ArticleModerateJain P, et al.2022-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is IFN‑γ1b officially approved to treat?
Interferon gamma‑1b is approved for chronic granulomatous disease, a rare immunodeficiency where it reduces serious infections by enhancing phagocyte function.
How does IFN‑γ1b help patients with chronic granulomatous disease?
It stimulates the NADPH‑oxidase system in phagocytes, restoring the ability to produce reactive oxygen species that kill bacteria and fungi, thereby lowering infection frequency and hospital stays.
Can IFN‑γ1b cure idiopathic pulmonary fibrosis?
Current clinical data are mixed; while a large trial suggested a modest survival benefit in early disease, consistent improvements in lung function have not been demonstrated, and the therapy remains investigational.
Is IFN‑γ1b used in bone disorders?
In infantile TCIRG1‑related osteopetrosis, IFN‑γ1b may be employed as a temporary bridge to hematopoietic stem‑cell transplantation, but it is not a definitive cure and evidence is limited to expert guidance.
What side effects should patients expect?
Patients commonly experience flu‑like symptoms such as fever, chills, headache, and mild injection‑site redness. These effects are usually brief and can be managed with simple supportive care.
What is Interferon gamma-1b?
Interferon gamma‑1b (IFN‑γ1b) is a recombinant cytokine prescribed for chronic granulomatous disease (CGD) and investigated for other rare disorders. It is administered by injection to boost immune cell function, reduce serious infections in CGD, and has been studied as a potential antifibrotic agent in idiopathic pulmonary fibrosis and as a bridge therapy before hematopoietic stem‑cell transplantation in infantile osteopetrosis.
What is Interferon gamma-1b used for?
Interferon gamma-1b is educationally associated with: Reduction of serious infections in chronic granulomatous disease, Antiviral / antitumor immunotherapy, Adjunct in refractory infections, Chronic Granulomatous Disease, Severe Malignant Osteopetrosis, Treatment of idiopathic pulmonary fibrosis, Delay of disease progression in severe malignant osteopetrosis. Educational only — not medical advice.
How is Interferon gamma-1b administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of Interferon gamma-1b?
Reported adverse effects include: Elevated liver enzymes (AST/ALT), Injection site reactions, Central nervous system effects (decreased mental status, gait disturbance, dizziness), Neutropenia / thrombocytopenia, Neutropenia, Flu-like symptoms (fever, chills, myalgia, headache, fatigue), Injection site reaction, Elevated liver enzymes, Flu‑like syndrome (fever, chills, myalgia), Cardiovascular effects (hypotension, tachycardia, syncope). This list is not exhaustive — consult a qualified clinician.
Who should avoid Interferon gamma-1b?
Recorded contraindications: Pre-existing severe neurological or seizure disorders, Hypersensitivity to interferon gamma-1b, Severe hepatic impairment, Severe autoimmune disease, Pre-existing severe cardiac disease, Hypersensitivity to interferon-gamma or E. coli-derived proteins. Consult a qualified clinician before use.